ALKERMES | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Acadia Pharmaceuticals USD 755.99M 190.66M 2024-12
ALKERMES USD 291.15M 636.63M 2024-12
Amgen USD 11.97B 2.96B 2024-12
Biogen USD 2.38B 675.8M 2024-12
BioMarin Pharmaceutical USD 613.22M 324.54M 2024-12
Bristol-Myers Squibb USD 10.88B 529M 2025-03
Eli Lilly USD 3.09B 175.1M 2025-03
Gilead Sciences USD 7.93B 2.06B 2025-03
Ionis Pharmaceuticals USD 264.19M 22.12M 2025-03
J&J USD 38.47B 32.35B 2025-03
Malin Corporation EUR 35.7M 6.4M 2024-06
Merck USD 13.24B 1.35B 2024-12
Neurocrine Biosciences USD 233M 116.1M 2024-12
Otsuka Holdings JPY 407.5B 18.68B 2025-03
Pfizer USD 1.04B 49M 2024-12
Regeneron Pharmaceuticals USD 3.09B 14.82B 2025-03
Vertex Pharmaceuticals USD 4.57B 669.6M 2024-12



ALKERMES Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - May 2025.